Form 4: Axsome Director Sells Shares to Cover Tax Obligations

Axsome Therapeutics director Mark Coleman converted 1,429 restricted stock units and sold 643 shares to satisfy tax liabilities under a Rule 10b5-1 plan.

Summary

• Director Mark Coleman converted 1,429 Restricted Stock Units (RSUs) into common stock on June 8, 2026, following a one-year vesting period.
• On June 10, 2026, 643 shares were sold at a weighted average price of $249.00 per share.
• The sale was conducted specifically to cover tax withholding obligations associated with the RSU settlement.
• The transaction was executed under a pre-approved Rule 10b5-1 trading plan, which is now completed.
• Following the transactions, the reporting person directly owns 30,389 shares and indirectly controls 403,856 shares through an entity.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event; while a sale occurred, it was non-discretionary for taxes, and the director remains heavily invested with over 400,000 shares.

Positives

• The director maintains a substantial indirect ownership of 403,856 shares, indicating significant long-term alignment with shareholders.
• The sale was non-discretionary, intended only to satisfy tax obligations rather than a voluntary divestment of equity.
• The use of a Rule 10b5-1 plan provides transparency and mitigates concerns regarding the timing of the trade.

Negatives

• The sale resulted in a minor reduction of the director's direct shareholding position.
• The sale price of $249.00 represents the lower end of the reported intraday range of $245.17 to $253.04.

Risks

• Market volatility may affect the valuation of the remaining 434,245 total shares held by the director.
• The completion of the current 10b5-1 plan means future sales would require the establishment of a new plan or be subject to standard trading window restrictions.

Future Outlook

The completion of the 10b5-1 plan suggests that immediate further sales by this director are not scheduled under this specific arrangement. The significant remaining stake suggests continued confidence in the company's long-term trajectory.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Shares were sold to cover taxes associated with the settlement of RSUs that were initially granted on June 6, 2025.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard practice in the biotechnology sector, where equity-based compensation is a primary tool for retaining board members and executives. Such sales are generally viewed as neutral by the market as they do not reflect a change in the insider's investment thesis.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a best-practice standard for directors of NASDAQ-listed companies like Axsome Therapeutics to avoid allegations of insider trading.
• The retention of over 99% of total beneficial interest (direct and indirect) following a tax-related sale is consistent with high-conviction insider behavior seen at peer firms like Sage Therapeutics or Acadia Pharmaceuticals.

Related Party Transactions

• Mark Coleman holds 403,856 shares through an entity over which he exercises voting and dispositive power.

Stakeholder Impact

• Shareholders should view this as a routine administrative transaction with no impact on company operations or strategy.

Next Steps

• Monitor for the establishment of any new 10b5-1 trading plans by company insiders.
• Track upcoming clinical or regulatory milestones that may influence the value of the director's remaining holdings.

Key Dates

Recommendation

The transaction is a routine tax-related sale and does not provide a new signal regarding the company's fundamental value. Investors should maintain their current positions based on the company's clinical pipeline and commercial performance.

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Form 4, Mark Coleman, Restricted Stock Units, 10b5-1 Plan, Biotechnology, Executive Compensation